The global gene-expression profiles of U-937 human macrophages treated with Tat peptide and Tat-FITC conjugate

Journal of Drug Targeting

Volumn 20, Issue 6, 2012, Pages 515-523

  Lin, Chia Wei ^a   Kuo, Jung Hua Steven ^b   Jan, Ming Shiou ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

Cell penetrating peptides; Conjugation; FITC; Macrophage; Microarray; Tat

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; TRANSACTIVATOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CASP8 GENE; CONTROLLED STUDY; CRLF1 GENE; FNAR2 GENE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE FUNCTION; GENOME; HELA CELL; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MACROPHAGE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CASPASE 8; CELL CULTURE TECHNIQUES; CELL SURVIVAL; CELL-PENETRATING PEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; FLOW CYTOMETRY; FLUORESCEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; MACROPHAGES; MICROARRAY ANALYSIS; PEPTIDE FRAGMENTS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, CYTOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; U937 CELLS;

EID: 84861828020     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.693496     Document Type: Article

References (20)

1. Chauhan A, Tikoo A, Kapur AK, Singh M. (2007). The taming of the cell penetrating domain of the HIV Tat: myths and realities. J Control Release, 117, 148-162.
2. de Weerd NA, Samarajiwa SA, Hertzog PJ. (2007). Type I interferon receptors: biochemistry and biological functions. J Biol Chem, 282, 20053-20057.
3. Ekokoski E, Aitio O, Törnquist K, Yli-Kauhaluoma J, Tuominen RK. (2010). HIV-1 Tat-peptide inhibits protein kinase C and protein kinase A through substrate competition. Eur J Pharm Sci, 40, 404-411.
4. El-Andaloussi S, Järver P, Johansson HJ, Langel U. (2007). Cargo-dependent cytotoxicity and delivery efcacy of cell-penetrating peptides: a comparative study. Biochem J, 407, 285-292.
5. Elson GC, Lelièvre E, Guillet C, Chevalier S, Plun-Favreau H, Froger J, Suard I, de Coignac AB, Delneste Y, Bonnefoy JY, Gauchat JF, Gascan H. (2000). CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nat Neurosci, 3, 867-872.
6. Fisher AA, Ye D, Sergueev DS, Fisher MH, Shaw BR, Juliano RL. (2002). Evaluating the specifcity of antisense oligonucleotide conjugates. A DNA array analysis. J Biol Chem, 277, 22980-22984.
7. Fonseca SB, Pereira M P, Kelley SO. (2009). Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev, 61, 953-964.
8. Fotin-Mleczek M, Welte S, Mader O, Duchardt F, Fischer R, Hufnagel H, Scheurich P, Brock R. (2005). Cationic cell-penetrating peptides interfere with TNF signalling by induction of TNF receptor internalization. J Cell Sci, 118, 3339-3351.
9. Frisch SM. (2008). Caspase-8: fy or die. Cancer Res, 68, 4491-4493.
10. Hardy MP, Owczarek CM, Trajanovska S, Liu X, Kola I, Hertzog PJ. (2001). The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood, 97, 473-482.
11. Heitz F, Morris MC, Divita G. (2009). Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol, 157, 195-206.
12. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA. (2003). Identifying biological themes within lists of genes with EASE. Genome Biol, 4, R70.
13. Kuo JH, Jan MS, Lin YL, Lin C. (2009). Interactions between octaarginine and U-937 human macrophages: global gene expression profling, superoxide anion content, and cytokine production. J Control Release, 139, 197-204.
14. Moschos SA, Jones SW, Perry MM, Williams AE, Erjefalt JS, Turner JJ, Barnes PJ, Sproat BS, Gait MJ, Lindsay MA. (2007). Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem, 18, 1450-1459.
15. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chernomordik LV, Lebleu B. (2003). Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem, 278, 585-590.
16. Sawant R, Torchilin V. (2010). Intracellular transduction using cell-penetrating peptides. Mol Biosyst, 6, 628-640.
17. Schindler C, Levy DE, Decker T. (2007). JAK-STAT signaling: from interferons to cytokines. J Biol Chem, 282, 20059-20063.
18. Torchilin V P. (2008). Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev, 60, 548-558.
19. Waldeck W, Pipkorn R, Korn B, Mueller G, Schick M, Tóth K, Wiessler M, Didinger B, Braun K. (2009). Transporter molecules infuence the gene expression in HeLa cells. Int J Med Sci, 6, 18-27.
20. Yang Y, Tikhonov I, Ruckwardt TJ, Djavani M, Zapata JC, Pauza CD, Salvato MS. (2003). Monocytes treated with human immunodefciency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism. J Virol, 77, 6700-6708.